Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Gastroesophageal Reflux Disease in Infants
2022-502770-16-00Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of omeprazole in gastroesophageal reflux disease (GERD) and cow's milk protein allergy (CMPA) (3 arms), sponsored by University Hospital Odense. Planned start Nov 2024; status: authorised.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)cow's milk protein allergy (CMPA)
Beyond the preview
Go deeper on 2022-502770-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502770-16-00.